Click here to receive MS news via e-mail
The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommendZinbryta (daclizumab) to be available to multiple sclerosis (MS) patients through the country’s health service. The decision came in a first stage of the drug’s review process, and NICE is welcomingfeedback from patient groups, healthcare professionals, and others.
In making this initial decision, NICE reported that issues linked to the clinical and cost-effectiveness models presented by Zinbryta’s developer, Biogen, presented a high degree of uncertainty. Biogen has been asked to submit further evidence.
“The committee concluded that daclizumab was not cost effective for patients without more active disease … [and] that it had not been presented with robust evidence that daclizumab was cost effective for people with more active disease … Because the committee considered the analyses to be highly uncertain or not relevant to the NHS [National Health System], it invited the company to submit revised analyses,”NICE concluded in its report.
MS Views and News
Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews